Navigation Links Provides Revenue Guidance for FY 2010

SCOTTSDALE, Ariz., Feb. 20 /PRNewswire-FirstCall/ --, Inc., (OTC Bulletin Board: EFSF) an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products, outlined its growth objectives for the fiscal year ending April 30, 2010 during its regularly scheduled monthly investor call, held on February 17, 2009. intends to increase revenues by improving the visibility of its products. The Company's conservative revenue forecast for fiscal 2010 is $3 million. The stretch goal is $5 million. The Company expects that the ongoing recession may negatively impact gross margins and is conservatively forecasting $1.65 million, or 55%, of gross margin on its products. The Company will endeavor to maintain its operating expenses within the gross margin in order to generate positive operating income. Based on initial forecasting, the Company plans to allocate 15% (approximately $450,000) to research, development and clinical efforts, 25% (approximately $750,000) to marketing and sales and 10% (approximately $300,000) to general and administrative activities including business/partnership development. This tentatively would yield a 5% (approximately $150,000) EBIDA. Separately, the Company's goal is to close at least two major partnerships in 2010, which could positively impact the net profits.

A replay of the conference call is available until February 24, 2009 at 11:59 PM EST. The replay number is 1-877-660-6853 (US) and 1-201-612-7415 (international). To listen to the replay, please provide the account code 3055 and conference ID number 312810.

About, Inc. is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. The Company recently announced a pending merger with Freedom2, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets worldwide. The merger is on track to close on or before February 28, 2009.


Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Investor Relations Contacts:

    Blair Barnes, CFO
    Freedom2, Inc.
    Ph: 856-354-0707 ext. 201

    Stephanie Carrington/Amy Glynn
    The Ruth Group
    Ph: 646-536-7017/7023

Press Contact:

    Pat Arcand
    Arcand & Madison
    Ph: 617-576-7777

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Restructures purEffect(TM) Marketing Agreement with CK41
2. Engages IridiumGroup to Develop New Brand Identity to Match Future Company Direction
3. Selects Arcand & Madison as Public Relations Counsel and The Ruth Group as Investor Relations Counsel
4. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
5. Landmark Trial Provides Vital Information for Cardiac Disease Treatment
6. Renaissance Laser & Vein Institute ( Provides Top Notch Varicose Vein Treatment
7. Supplement of probiotics provides a new therapy for ulcerative colitis
8. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
9. PhoneCaption Provides Free Captioning Services for Deaf and Hard of Hearing
10. Medicaid Health Plans of America Lauds Stimulus Bills Conference Agreement Which Provides $90 Billion in Medicaid Relief for Nations Most Vulnerable Citizens
11. JAMA Article Provides Guidance to Physicians on End-of-Life Care
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday 27 ... NASDAQ to educate the personnel on spinal decompression therapy and offer his professional ... nonsurgical procedure. The benefits come from creating negative intradiscal pressure which is conducive ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... rural West Tennessee to receive Gigabit Internet through a partnership this year with ... largest cities, Henderson is an attractive destination for entrepreneurs who want to build ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Florida Hospital Tampa is the ... of obesity in the state of Florida. , vBloc® Therapy is a vagal blocking therapy, ... 18 years with a body mass index (BMI) of at least 40 to 45 kg, ...
(Date:12/1/2015)... ... ... Califia Farms , one of the fastest growing natural beverage companies ... in Beverage World Magazine’s Global Packaging Design Awards, taking home the Gold in the ... a 2015 U.S.A. Taste Champion in the American Masters of Taste Championships for its ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... WellStar Health System has signed a definitive ... Tenet Healthcare,s five metro Atlanta ... move following the conclusion of the due diligence period. ... and patient safety programs that have resulted in increased ... --> --> With ...
(Date:12/1/2015)... 2015  Eyeon Therapeutics has received a Notice ... based on a charged hydrophilic polymer developed at ... product has been shown to be safe and ... Mark Mitchnick , MD, CEO states, "This second ... polymers in conjunction with a therapeutic agent.  Nanoparticles ...
(Date:12/1/2015)... , Dec. 1, 2015 Pharma Tech Outlook ... Top 10 Clinical Data Management Solution Providers - 2015 ... distinguished panel comprising CEOs, CIOs, VCs, analysts, and the ... illustrious list of top 10 clinical data management solution ... on pages 14 and 36 respectively). ...
Breaking Medicine Technology: